StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research report report published on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright lowered their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a research note on Wednesday, August 7th.
Read Our Latest Stock Report on Minerva Neurosciences
Minerva Neurosciences Stock Down 3.2 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Equities research analysts expect that Minerva Neurosciences will post -2.26 EPS for the current fiscal year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Featured Stories
- Five stocks we like better than Minerva Neurosciences
- Low PE Growth Stocks: Unlocking Investment Opportunities
- The Average 401k Balance by Age Explained
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.